Midday Report: Aptorum (APM) Gains on June 21

Equities Staff  |

Aptorum Group Ltd - Class A (NASDAQ: APM) shares have risen 5.22%, or $0.06 per share, as on 11:43:32 est today. Opening the day at $1.19, 7,817 shares of Aptorum have been traded today and the stock has ranged between $1.27 and $1.12.  

So far this year the company has a YTD change of 23.33%.

Aptorum expects its next earnings on 2022-09-01.

For technical charts, analysis, and more on Aptorum visit the company profile.

About Aptorum Group Ltd - Class A

Aptorum Group Limited  is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through programs such as the systematic screening of existing approved drug molecules and microbiome-based research platform for treatments of metabolic diseases. Aptorum also has projects focused on microbiome research and the commercialization of a natural supplement product targeted for women undergoing menopause and experiencing related symptoms.

To get more information on Aptorum Group Ltd - Class A and to follow the company's latest updates, you can visit the company's profile page here: Aptorum Group Ltd - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content